-
Sector Analysis
Alzheimer’s Disease Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2030
Alzheimer’s Disease Market Report Overview Alzheimer’s Disease and MCI market size across the 8MM was valued at $2.2 billion in 2020 and is expected to achieve a CAGR of more than 19% during 2020-2030. AD is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. Mild cognitive impairment (MCI) is a phase of the AD continuum in which a gradually progressive cognitive decline occurs and may even become clinically relevant. Alzheimer’s Disease Market Outlook,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tricaprilin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tricaprilin Drug Details Tricaprilin (AC-1204) is under development for the treatment of Alzheimer's disease,...
-
Product Insights
Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity. The Migraine pipeline drugs market research report provides comprehensive information on the therapeutics...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, anxiety, loss of consciousness, and contraction or jerking of body muscles. The Epilepsy Drugs in Development market research report provides an overview of the Epilepsy pipeline landscape. The report provides comprehensive information on the...
-
Product Insights
Alzheimer’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alzheimer's disease is a progressive, degenerative condition causing damage to memory and behavior due to the attack on the neurons. Predisposing factors include age, heredity, cardiovascular diseases or diabetes, and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability, and aggressiveness. The Alzheimer’s Disease Drugs in Development market research report provides an overview of the Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug...
-
Sector Analysis
Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2028
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of the disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation, either by a home care professional or a family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL) for both patients and their caretakers....
-
Product Insights
Dysgeusia (Taste Disorders) Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Dysgeusia (Taste Disorders) Global Clinical Trials Review, H1, 2019" provides an overview of Dysgeusia (Taste Disorders) clinical trials scenario. This report provides top line data relating to the clinical trials on Dysgeusia (Taste Disorders). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Age Related Memory Impairment Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Age Related Memory Impairment Global Clinical Trials Review, H2, 2018" provides an overview of Age Related Memory Impairment clinical trials scenario. This report provides top line data relating to the clinical trials on Age Related Memory Impairment. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...